A day before a massive countrywide vaccination drive against coronavirus is set to commence, Union Health Minister Harsh Vardhan on Friday said the step is probably the beginning of the end of COVID-19.
India is set to begin the much awaited COVID-19 vaccination drive on January 16. Two indigenously developed coronavirus vaccines Covishield and Covaxin will be administered to nearly 3 crore healthcare and frontline workers both in government and private sectors during the first phase.
At what cost is govt sourcing Serum s Covishield, Bharat Biotech s Covaxin – Explained
Premium
A health worker shows a box containing COVID-19 vaccine inside cold storage at Civil Hospital in Ahmedabad,
(AP)
The government is sourcing a total of 55 lakh doses from Hyderabad-based Bharat Biotech s Covaxin vaccine
The health ministry today said that 110 lakh (or 1.1 crore) doses of COVISHIELD vaccine are being procured from SII at the cost of Rs. 200/ dose (excluding taxes)
Share Via
Read Full Story
As the country gears up for mega Covid-19 vaccination drive slated to start from 16 January, the Union Health Ministry on Tuesday gave a detailed clarification on the Indian prices of the two Covid-19 vaccines approved for emergency use authorization.
Pune (Maharashtra) [India], January 12 (ANI): The first consignment containing vials of Covishield vaccine were dispatched from the Serum Institute of India here in the early hours of Tuesday, ahead of the January 16 launch of the nationwide vaccination drive.
COVID-19 vaccine: AstraZeneca seeks EU approval for Oxford vaccine
Premium
(REUTERS)
Britain, Argentina and India had earlier approved the emergency marker use of AstraZeneca-Oxford coronavirus vaccine
Share Via
Read Full Story
AstraZeneca and Oxford University had filed a formal bid for authorisation for their coronavirus vaccine, the European Medicines Agency said on Tuesday. A decision could come by 29 January, the agency added. EMA has received an application for conditional marketing authorisation for a COVID-19 vaccine developed by AstraZeneca and Oxford University, the Amsterdam-based regulator said in a statement. An opinion on the marketing authorisation could be issued by 29 January. provided that the data submitted on the quality, safety and efficacy of the vaccine are sufficiently robust and complete, it said.